Trump officials exerting unprecedented control over CDC scientific journal
The Trump administration's moves to control the research published by the agency ends a decades-long streak of independence for the journal, known as the MMWR.
Health officials and experts have long considered the MMWR as the "voice of CDC" and a respected source where federal scientists release research of public health importance. It ranks as among the most-cited health journals in the world.
"The MMWR has lost its autonomy," one health official told CBS News.
Efforts by Trump officials to control the publication have stalled the release of three studies about bird flu for weeks, as the virus continues spreading through wild birds, poultry farms and cows around the country.
That delay was initially attributed to the communications "pause" ordered by the Department of Health and Human Services, which stalled many releases across the government.
Spokespeople for the CDC and HHS did not immediately respond to requests for comment.
Trump officials initially said the gag order was needed for the administration to catch up in staffing its public relations team to oversee the vast amount of communications coming out of the nations' federal health agencies.
But as that pause has started to lift, Trump officials at HHS, and acting CDC Director Susan Monarez, refused repeated requests by career health officials to publish the completed research, officials say.
The stalled research includes findings about pet cats owned by dairy workers being infected with bird flu, plus wastewater testing results and antibody testing of cow veterinarians.
Instead, health officials say Monarez relayed orders by the Trump administration to come up with research to publish this week about the health risks from wildfires, days after President Trump criticized California's Democratic Governor Gavin Newsom's handling of fires in the state.
Federal scientists say they scrambled to find studies to comply with the order, which was unexpected and not related to any studies that had been scheduled to come out.
The research that was ultimately published looked at exposure to worrying chemicals for firefighters who responded to the 2023 wildfires in Hawaii and emergency room visits in Los Angeles during the wildfires.
Multiple health officials said they complied fearing their jobs. Scientists within the agency say they have been bombarded with daily requests to accept the "fork in the road" offer to resign by the Trump administration's Department of Government Efficiency, or DOGE, task force, headed by Elon Musk.
Glimpse at a study taken offline
A technical glitch resulted in a table from one of the bird flu studies accidentally being published on Thursday, before officials scrambled to take it down.
That bird flu study was supposed to lay out the details of an investigation into how two indoor cats could have contracted the virus. One of the cats' owners was a dairy worker who transported unpasteurized raw milk, which health officials warn is one of the main ways that H5N1 bird flu virus is spreading between farms in the U.S.
Multiple federal health officials and outside experts have unsuccessfully lobbied the Trump administration to allow the publication to maintain its independence, citing the importance of allowing federal public health researchers to publish their findings without fearing political interference.
While researchers often have to jump through multiple hoops of "clearance" within the agency to satisfy questions and concerns raised by scientists and career health officials about the accuracy of their research, officials said political appointees usually steered clear of meddling in its content.
Now health officials fear that a precedent has been set for the Trump administration to cross further lines in its attempts to influence the research and data published by the CDC.
Previous efforts by Trump-appointed officials to exert control over the publication came under scrutiny during the COVID-19 pandemic, in Mr. Trump's first term, after aides sought to influence reports at the time.
It is now unclear to co-authors of the bird flu research outside the agency when the research will ever be published, weeks after it was ready to go.
"The study is completed and was to be published in MMWR last month until the order from the new administration halted communication from CDC," K. Fred Gingrich II, executive director of the American Association of Bovine Practitioners, said in an email.
The association had worked with Ohio's health department and the CDC to sample the blood of veterinarians who treat cows at an annual conference late last year, looking for antibodies that would help answer an outstanding question: had bird flu cases infected veterinarians under the radar?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
3 Medical Stocks to Consider as Markets Take a Breather
The broader indexes have cooled off in the last few trading sessions after what was another pleasant month for the stock market in July. While the market has been able to shrug off trade war concerns on the way to a historic rebound, President Trump has officially signed an executive order to hit most of the United States' trading partners with tariff hikes, which ignited a pullback on Friday as July's Jobs Report came in weaker than expected. Considering the benchmark S&P 500 and the tech-centric Nasdaq looked due for a breather after spiking more than +10% in the last three months, investors may be scoping out some defensive positions. That said, these medical sector stocks may continue to provide this defensive safety, as there will always be a constant need for health care. CVS Health Zacks Rank #2 (Buy) CVS Health's CVS transformation into an innovative pharmacy company with integrated offerings across the entire spectrum of pharmacy care is paying off. Thanks to strong earnings, raised guidance, and renewed investor confidence, CVS stock has surged over +30% this year but still trades at just 10X forward earnings and offers a very generous 4.28% annual dividend yield. In addition to sporting a Zacks Rank #2 (Buy), CVS stock currently checks an overall 'A' VGM Zacks Style Scores grade for the combination of Value, Growth, and Momentum. Image Source: Zacks Investment Research Johnson & Johnson Zacks Rank #2 (Buy) Pharmaceutical giant Johnson & Johnson JNJ checks the value box, with a reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield. Furthermore, investors seemed to have flocked to Johnson & Johnson stock earlier in the year during heightened market volatility, and JNJ is still up +15% in 2025 to top the S&P 500 and Nasdaq's returns of roughly +7%. Although Johnson & Johnson's growth has slowed, steady top and bottom line expansion is still in the forecast, and the medical leader has one of the most diversified business models. Having more than 275 subsidiaries, Johnson & Johnson's pipeline of drugs/treatments covers neuroscience and mental health, oncology, immunology, pulmonary hypertension, cardiovascular, rare, and infectious diseases. Image Source: Zacks Investment Research Tenet Healthcare Zacks Rank #1 (Strong Buy) We'll round out the list with Tenet Healthcare THC, an investor-owned health care services company that owns and operates general hospitals and health care facilities for urban and rural communities in numerous states. Boasting a Zacks Rank #1 (Strong Buy), THC stock is benefiting from a very pleasant trend of positive earnings estimate revisions. With Tenet Healthcare's annual earnings now expected to leap 25% in fiscal 2025 to $14.92 per share, it's noteworthy that these EPS revisions have climbed 17% in the last 60 days from estimates of $12.69 two months ago. Plus, THC is up +25% YTD and trades at 10X forward earnings. Strongly suggesting Tenet Healthcare's impressive stock performance should continue, FY26 EPS is projected to expand another 4% to $15.48, and estimates have spiked 14% in the last 60 days. On top of being a 'feel-good' investment in regard to Tenet Healthcare reaching underserved communities, THC checks the fundamental trading boxes with an 'A' VGM Zacks Style Scores grade. Image Source: Zacks Investment Research Bottom Line Hopefully, the excitement for AI-driven growth will continue to push the broader market higher, but these top medical stocks can provide the defensive safety that investors may need with volatility starting to resurface amid President Trump's tariff hikes and last month's unfavorable jobs report. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Washington Post
2 hours ago
- Washington Post
States sue Trump administration over access to care for transgender youths
A coalition of more than a dozen states sued the Trump administration on Friday over health care for transgender young people, claiming the White House has 'relentlessly, cruelly, and unlawfully targeted transgender individuals' since President Donald Trump took office. The lawsuit, filed in federal court in Massachusetts, seeks to have part of one executive order issued in January declared unconstitutional. The order targets gender-affirming care provided to people under the age of 19, such as puberty blockers, hormone therapy and surgical procedures, which it refers to as 'mutilation.' The lawsuit also asks the court to declare unlawful the Justice Department's targeting of providers of gender-affirming care. The section of the order that is being challenged directs the Justice Department to use laws such as the Food, Drug and Cosmetic Act, those against female genital mutilation, and child custody legislation to carry out the administration's aims. 'It is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called 'transition' of a child from one sex to another,' Trump's order says, calling the treatments 'a stain on our Nation's history.' The states of Massachusetts, California, New York, Connecticut, Illinois, Delaware, Hawaii, Maine, Maryland, Michigan, Nevada, New Jersey, New Mexico, Rhode Island and Wisconsin, as well as the District of Columbia and Josh Shapiro in his capacity as Pennsylvania governor, filed suit. The lawsuit, filed against Trump, the Justice Department and Attorney General Pam Bondi, argues that the executive order conflicts with states' remit to regulate and police medicine and violates the 10th Amendment, which protects states' powers, and is in conflict with many state antidiscrimination laws. Nearly every major medical association endorses the availability of gender-affirming care for transgender young people, citing reductions in depression, substance abuse and suicide attempts. 'Empirical evidence has demonstrated that trans and nonbinary gender identities are normal variations of human identity and expression,' the American Medical Association has said. But the issue, and others related to transgender people, has animated conservatives. Trump has said he wants the 'official policy of the United States' to be that there are only two genders and has referred to being transgender as a 'falsehood.' The administration has moved to ban transgender service members from the military, relocate incarcerated transgender women into men's prisons and bar transgender people from using restrooms that align with their gender identity in federal buildings, among a slew of anti-trans measures, many of which have been challenged in court. After the January order, the lawsuit says, the Justice Department began 'intimidating providers into ceasing care through threats of civil and criminal prosecution.' 'These threats have no basis in law,' the complaint says. 'No federal law prohibits, much less criminalizes, the provision or receipt of gender-affirming care for transgender adolescents.' Puberty blockers temporarily inhibit sex hormones, such as estrogen and testosterone, and other hormone therapies introduce them to the body. Gender-affirming surgeries, such as breast reductions for transgender men, are rarely performed on minors. White House spokesperson Taylor Rogers said in an email that 'everyday Americans resoundingly support' the administration's actions. 'The President has the lawful authority to protect America's vulnerable children through executive action, and the Administration looks forward to ultimate victory on this issue,' she added. In June, the Supreme Court upheld a ban on gender-affirming care for minors in Tennessee.
Forbes
3 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
